Detalhe da pesquisa
1.
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.
Gynecol Oncol
; 185: 186-193, 2024 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38447347
2.
Alcohol intake and the risk of epithelial ovarian cancer.
Cancer Causes Control
; 34(6): 533-541, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36933150
3.
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
Gynecol Oncol
; 170: 241-247, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36736157
4.
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100.
Gynecol Oncol
; 178: 119-129, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37862791
5.
Leiomyoma With Massive Lymphoid Infiltration: 2 Cases With Lymphocytic Vasculopathy and Angiocentric Germinal Centers.
Int J Gynecol Pathol
; 42(2): 155-158, 2023 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35348475
6.
Vulvar Squamous Cell Carcinoma With Sarcomatoid Features are HPV-independent Lesions: A Subset are Also Associated With TP 53-independent Lesions and Radiation Therapy.
Int J Gynecol Pathol
; 42(2): 207-211, 2023 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35639348
7.
Endometrial carcinosarcoma.
Int J Gynecol Cancer
; 33(2): 147-174, 2023 02 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36585027
8.
Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.
Gynecol Oncol
; 166(3): 425-431, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35803835
9.
Clear cell carcinoma of the endometrium.
Gynecol Oncol
; 164(3): 658-666, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35063279
10.
Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities.
J Pathol
; 253(1): 41-54, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32901952
11.
Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses.
Mod Pathol
; 34(1): 194-206, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32724153
12.
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
Gynecol Oncol
; 163(3): 490-497, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34602290
13.
Uterine serous carcinoma.
Gynecol Oncol
; 162(1): 226-234, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33934848
14.
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
Gynecol Oncol
; 161(3): 668-675, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33752918
15.
SATB2 Expression in Uterine Sarcoma: A Multicenter Retrospective Study.
Int J Gynecol Pathol
; 40(5): 487-494, 2021 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33720083
16.
A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis.
Int J Mol Sci
; 22(10)2021 May 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34070214
17.
Lifetime recreational moderate-to-vigorous physical activity and ovarian cancer risk: A case-control study.
Int J Cancer
; 146(7): 1800-1809, 2020 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31199510
18.
Low junctional adhesion molecule-A expression is associated with an epithelial to mesenchymal transition and poorer outcomes in high-grade serous carcinoma of uterine adnexa.
Mod Pathol
; 33(11): 2361-2377, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32514162
19.
EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer.
Gynecol Oncol
; 156(2): 301-307, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31870556
20.
Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.
Gynecol Oncol
; 157(1): 12-20, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31954537